Diligence memo · auto-generated · as of July 3, 2026
Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Inhibikase Therapeutics, Inc. operates in Pharmaceuticals, based in Atlanta.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Inhibikase Therapeutics, Inc. has raised $12M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $8.0M on 2024-05-20.
Most recent recorded round closed around 2024-05-20.
Valuation (modeled)modeled
Provath models Inhibikase Therapeutics, Inc. at approximately $43M (range $9.2M–$96M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.33× the median modeled value of Series A Pharmaceuticals companies in 2022–2024 (64 peers) — value vs value, same stage and era. Within the normal band (133% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 16 months.
Last raise 2.1 yr ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
The last round stepped up 1.9× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 58% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 40% of those peers.
Closest niche peers: Hallux, Inc., Enalare Therapeutics Inc., Silver Creek Pharmaceuticals, Inc., NQ PE Project Stingray Parent, L.P., Acta Pharmaceuticals, Inc..
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.